Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
FDA has set a target action date of December 16, 2023NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foamIf approved, roflumilast foam... | April 18, 2023